Roth MKM reiterates a Buy rating on OptimizeRx (OPRX) with a $16 price target following the Q4 report. The company reported “strong” results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback